Sponsors / TNXP
TNXP

Tonix Pharmaceuticals, Inc.

Company identity has not yet been verified

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
16Trials in this database
0Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related ConditionsNCT02277704Tonix Pharmaceuticals, Inc.Phase 2Completed2016-05Actual
Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related ConditionsNCT02421679Tonix Pharmaceuticals, Inc.Phase 2Completed2016-05-26Actual
A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgiaNCT02436096Tonix Pharmaceuticals, Inc.Phase 3Completed2016-09Actual
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia PatientsNCT02589275Tonix Pharmaceuticals, Inc.Phase 3Completed2016-09-28Actual
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With FibromyalgiaNCT02829814Tonix Pharmaceuticals, Inc.Phase 3Terminated2016-09-13Actual
Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSDNCT03062540Tonix Pharmaceuticals, Inc.Phase 3Terminated2018-07-27Actual
12-Week Open-Label Extension Study of TNX-102 SL in PTSD PatientsNCT03110575Tonix Pharmaceuticals, Inc.Phase 3Terminated2018-07-27Actual
A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSDNCT03508700Tonix Pharmaceuticals, Inc.Phase 3Completed2019-09-30Actual
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSDNCT03841773Tonix Pharmaceuticals, Inc.Phase 3Terminated2020-04-24Actual
A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With FibromyalgiaNCT04508621Tonix Pharmaceuticals, Inc.Phase 3Completed2021-11-01Actual
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With FibromyalgiaNCT05273749Tonix Pharmaceuticals, Inc.Phase 3Completed2023-11-14Actual
A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 InfectionNCT05472090Tonix Pharmaceuticals, Inc.Phase 2Completed2023-07-12Actual
A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic MigraineNCT05679908Tonix Pharmaceuticals, Inc.Phase 2Completed2023-10-08Actual
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)NCT05686408Tonix Pharmaceuticals, Inc.Phase 2Completed2023-09-29Actual
Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)NCT06045793Tonix Pharmaceuticals, Inc.Phase 2Terminated2025-04-21Actual
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)NCT07621237Tonix Pharmaceuticals, Inc.Phase 2Recruiting2028-02Estimated

Latest recorded trial changes

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.